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Objectives The aim of the study was to evaluate the risk of cardiac events in patients with normal stress echocardiography
(SE) who attained maximal age-predicted heart rate (APHR) compared with those who did not in the setting of
both normal and abnormal SE.
Background SE is an important tool in the risk stratification and prognosis of patients with known or suspected coronary
artery disease (CAD). The prognostic value of a normal but submaximal SE (85% of maximal APHR) is
conflicting.
Methods PubMed, EMBASE, and CENTRAL were searched from 1980 to September 2011 for SE studies reporting cardiac
outcomes in patients with known or suspected CAD stratified by achieved APHR. Both hard events (cardiac
death and myocardial infarction) and total cardiac events (revascularization procedures in addition to hard
events) were analyzed separately. Data on all-cause mortality were obtained when available.
Results Fourteen studies with 11,542 patients followed up for a mean duration of 32 months fulfilled the inclusion
criteria. In 8 studies with 4,577 patients, the risk of hard events with normal SE (both exercise and dobut-
amine) was 70% higher in patients who achieved submaximal compared with those with maximal APHR
(annualized event rate 2.08% vs. 0.77%; p  0.0008; 95% confidence interval [CI]: 1.25 to 2.31). In 7 stud-
ies with 5,798 patients, the risk of total cardiac events with normal SE (both exercise and dobutamine) was
127% higher in patients who achieved submaximal compared with those with maximal APHR (annualized
event rate 1.87% vs. 1.02%; p  0.0001; 95% CI: 1.54 to 3.34). The risk of total cardiac events was 278%
higher in patients with abnormal SE with submaximal APHR compared with those with normal SE with sub-
maximal APHR (p  0.0001; 95% CI: 2.81 to 5.08). There was a trend toward increased all-cause mortality
in patients with normal SE with submaximal compared with maximal APHR (relative risk: 1.36; p  0.15;
95% CI: 0.89 to 2.09).
Conclusions Patients with submaximal APHR in the setting of normal SE have a higher risk of cardiovascular events than
those who attained maximal stress test. Thus, the results of submaximal APHR in the setting of normal SE
should be taken into consideration for more accurate risk stratification and prognosis. (J Am Coll Cardiol
2012;60:1393–401) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.041eStress echocardiography (SE) is an important tool in the risk
stratification and prognosis of patients with known or sus-
pected coronary artery disease (CAD) (1–4). Risk of cardiac
events range from 0.5% to 1.0% per year in patients undergo-
ing normal exercise SE (5,6) and 0.5% to 2.0% per year in
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Manuscript received June 13, 2012; accepted June 19, 2012.patients with normal dobutamine SE (7–9). The test is usually
considered nondiagnostic if the patient fails to achieve 85% of
the maximum age-predicted heart rate (APHR). The inci-
dence of submaximal stress testing has ranged from 9% (10) to
62% (11) in various studies. Patients on beta-blockers and
calcium channel blockers are less likely to achieve target heart
rate during stress testing, with a reported incidence of 5% to
40% (9,12–14). The data regarding the prognosis of patients
who achieve submaximal APHR with SE are conflicting and
controversial. In an earliest study by Sawada et al. (15), patients
who achieved 85% APHR (submaximal) during normal
xercise SE had a higher incidence of cardiac events compared
ith those who attained 85% of APHR (maximal) in the
I
n
b
o
f
b
n
c
a
a
a
f
c
e
p
t
o
f
d
o
R
W
r
F
p
1394 Makani et al. JACC Vol. 60, No. 15, 2012
Cardiac Outcomes and Submaximal Stress Echocardiography October 9, 2012:1393–401setting of normal SE (15). How-
ever recent studies (16,17) have
failed to show significant differ-
ence in cardiac outcomes between
these 2 groups. The objective of
the present study was to evaluate
the risk of cardiac events in pa-
tients with normal SE who at-
tained maximal APHR compared
with those who did not in the
setting of both normal and abnor-
mal SE.
Methods
Search strategy. We searched PubMed, EMBASE, and
Cochrane Central Register of Clinical Trials (Cochrane
Library Issue 5, 2011) using the terms “stress echocardiog-
raphy,” “exercise echocardiography,” “dobutamine echocar-
diography,” and “treadmill echocardiography.” We limited
our search to studies in humans and in peer-reviewed
journals from 1980 to September 2011. No language re-
striction was applied. The reference lists of identified
articles and bibliographies of original articles were also
reviewed. Trials in the abstract form without a published
manuscript were excluded for this analysis.
Data extraction. Two reviewers (D.H. and H.G.M.) ex-
tracted the data independently and in duplicate. Disagree-
ments were resolved by arbitration, and consensus was
reached after discussion. We extracted characteristics of
each trial, baseline demographics, duration of follow-up,
percent of patients not reaching 85% APHR, percent of
patients on beta-blockers, percent of patients with prior
myocardial infarction (MI), CAD, and all cardiac outcomes
for our analysis. Authors of the papers were individually
contacted by e-mail when the data were unclear or to obtain
additional data.
Selection criteria. Eligible trials had to fulfill the follow-
ing criteria for inclusion: 1) patients with known or
suspected CAD undergoing either exercise or dobut-
amine SE; 2) data on cardiac events available for patients
achieving 85% and 85% APHR with a normal stress
result; and 3) study duration of at least 6 months. Normal
SE was defined as having no inducible wall motion
abnormalities (WMAs). Resting WMAs without any
inducible ischemia were still considered normal SE.
Patients undergoing dipyridamole SE or SE immediately
after MI were excluded.
Outcomes. The primary outcome was hard cardiovascular
events, defined as a composite of nonfatal MI and cardiac
death. We evaluated total cardiac events, which included
revascularization procedures (percutaneous coronary inter-
vention or coronary bypass grafting) in addition to the hard
events. Additional data was obtained on all-cause mortality
Abbreviations
and Acronyms
APHR  age-predicted
heart rate
CAD  coronary artery
disease
MI  myocardial infarction
SE  stress
echocardiography
WMA  wall motion
abnormalitywhen available.Quality of studies. We assessed the quality of the studies
using the Newcastle-Ottawa Scale (NOS) (18). This quality
score was calculated on the basis of 3 major components of
cohort studies: selection of study groups (0 to 4 points),
comparability of study groups (0 to 2 points), and ascertain-
ment of the outcome of interest (0 to 3 points). Scores
ranged from zero (worst) to 9 (best). Studies with a score of
7 or more represented better methodological quality. Areas
of disagreement or uncertainty were resolved by discussion.
Statistical analysis. The statistical analysis was completed
in line with recommendations from the MOOSE (Meta-
Analysis of Observational Studies in Epidemiology) guide-
lines (19). Heterogeneity was assessed using I2 statistics. I2
is the proportion of total variation observed between trials
attributable to differences between trials rather than sam-
pling error (chance), and we considered I225% as low and
2 75% as high. The random-effects model of DerSimo-
ian and Laird (20) was used to calculate the effect sizes
ecause of known clinical and methodological heterogeneity
f the studies. A head-to-head comparison was completed
or hard events, total cardiac events, and all-cause mortality
etween patients achieving 85% and 85% APHR with
ormal SE. Similarly, a head-to-head comparison was
ompleted in patients achieving 85% APHR with both
bnormal and normal SE when data were available.
Annualized event rates for each study were calculated as
verages over the lengths of follow-up, and pooled summary
nnualized event rates (hard events and total cardiac events)
or normal SE with submaximal and maximal APHR were
alculated by weighing the rate by the inverse of variance of
ach trial. Publication bias was estimated visually by funnel
lots and/or using the Begg test and the weighted regression
est of Egger et al. (21).
Subgroup analysis was performed based on the presence
r absence of resting WMAs, mean age, duration of
ollow-up, and percent of patients on beta-blockers. The
ifference between the subgroups was estimated on the basis
f tests for interaction (22).
esults
e identified 1,845 articles, of which 159 abstracts were
etrieved and reviewed for possible inclusion (Online Fig.).
ourteen studies (6–11,13–16,23–26) (Table 1) with a total
atient population of 11,542, a mean age of 61  6 years,
51% men, and mean follow-up of 32 months fulfilled the
inclusion criteria. Among patients undergoing SE, 27%
failed to achieve APHR, 16% were on beta-blockers, and
another 21% had underlying CAD. Five studies used
exercise SE, 8 studies used dobutamine SE, and 1 study
used either exercise or dobutamine SE. Thirteen studies
were excluded because they did not meet the inclusion
criteria—4 were substudies (17,27–29) and another 9 failed
to provide data on patients with submaximal normal SE
(30–38).
General Characteristics of Included TrialsTable 1 General Characteristics of Included Trials
First Author,
Year (Ref. #) Patient Cohort
Total No. of
Patients
Follow-Up,
months
Mean Age,
yrs
Men,
%
Patients With
<85% APHR, %
Type of
Stress
Test
Patients on
BB, %
Patients With
MI, %
Patients With
CAD, %
Event Rate
After
Negative
Test, %
Annual
Event
Rate, % Cardiac Outcome
Quality
Assessment
Score*
Ballal et al.,
1997 (23)
Suspected or
known CAD
255 28 61 55 100 Dob 0 NR 55 NR NR Nonfatal MI,
cardiac death,
revascularization
4/1/3
Chaowalit et al.,
2006 (8)
Suspected or
known CAD
3,014 75.6 68 40 14 NL Dob 24 7 13 7.7 1.2 MI and
revascularization
4/2/2
Chuah et al.,
1998 (7)
Suspected or
known CAD
860 52 70 56 46 Dob 22 31 45 7.8 1.8 Nonfatal MI,
cardiac death
4/1/2
Chung et al.,
2004 (10)
Suspected or
known CAD
233 32 64 46 9 NL Ex or
Dob
NR 0 22 2.1 0.8 Nonfatal MI,
cardiac death
4/1/3
Geleijnse et al.,
1998 (13)
Suspected or
known CAD
200 21 59 43 11 NL Dob 35 11 20 1 0.6 Nonfatal MI,
cardiac death,
revascularization
4/1/2
Lauer et al.,
1998 (24)
Suspected or
known CAD
231 41 57 63 18 Ex 0 NR NR 9.9 2.9 Nonfatal MI,
cardiac death,
revascularization
4/2/3
Lerakis et al.,
2010 (25)
Suspected or
known CAD
204 11 54 72 13 NL Dob 12 NR 8 1.5 1.6 Nonfatal MI,
cardiac death
3/1/3
Marwick et al.,
1998 (9)
CRF and CAD
risk factors
193 38 63 38 36 Dob 19 31 35 12 3.8 Nonfatal MI,
cardiac death,
revascularization
2/1/3
McCully et al.,
1998 (6)
Suspected CAD 1,325 23 57 48 17 NL Ex 15 0 0 2 1 Nonfatal MI,
cardiac death,
revascularization
4/1/2
Peteiro et al.,
2010 (6)
Suspected or
known CAD
2,947 22.8 62 61 20 Ex 7 17 23 1.8 0.95 Nonfatal MI,
cardiac death,
all-cause
mortality
4/2/3
Rakhit et al.,
2006 (26)
CRF and CAD
risk factors
244 20 54 57 11 Dob 34 NR 31 9.2 5.5 Nonfatal MI,
cardiac death,
all-cause
mortality
3/1/2
Sawada et al.,
1990 (15)
Suspected CAD 160 28.4 53 52 31 NL Ex 24 NR NR 1.4 0.6 Nonfatal MI,
cardiac death,
revascularization
4/1/2
Srivastava et al.,
2008 (16)
Suspected or
known CAD
727 39 71 41 45 NL Dob NR 22 30 7.2 2.2 Nonfatal MI,
cardiac death
3/1/2
Syed et al.,
1998 (11)
Suspected or
known CAD
949 12 62 55 62 Ex 32 23 24 2.5 2.5 Nonfatal MI,
cardiac death,
revascularization
4/1/3
*Quality assessment score given in 3 parts: selection (0 to 4 points), comparability (0 to 2 points), and outcome (0 to 3 points).
APHR  age-predicted heart rate; BB  beta-blockers; CAD  coronary artery disease; CRF  chronic renal failure; Dob  dobutamine; Ex  exercise; MI  myocardial infarction; NL  normal; NR  not reported. 1395
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Cardiac Outcomes and Submaximal Stress Echocardiography October 9, 2012:1393–401Most of the studies included in this meta-analysis were
of high quality, with a NOS score 7, except 1 (9) with
a score of 6, as described in detail in Table 1.
Prognostic value of maximal versus submaximal normal SE.
HARD EVENTS (CARDIAC DEATH AND MI). Eight studies
ith 4,577 patients, mean age of 61 years, and mean
ollow-up of 30.4 months were included in this analysis.
he risk of hard events with normal SE (both exercise and
obutamine) was 70% higher in patients who achieved
ubmaximal APHR compared with those with maximal APHR
p 0.0008; 95% confidence interval [CI]: 1.25 to 2.31).
n 4 studies and 2,940 patients with normal exercise SE,
he risk of hard events was 95% higher in patients who
chieved submaximal APHR compared with those with
aximal APHR (p  0.02; 95% CI: 1.13 to 3.36).
Similarly in 5 studies with 1,637 patients with normal
dobutamine SE, the risk of hard events was 59% higher
in those who achieved submaximal APHR compared
with those with maximal APHR (p  0.01; 95% CI: 1.10
to 2.31) (Fig. 1).
The annualized incidence of hard events in patients with
normal SE with submaximal APHR was 2.08% (84 of 1,220
patients) compared with 0.77% in patients with maximal
APHR (92 of 3,357 patients). Patients with normal exercise
SE with submaximal APHR had an annual event rate of
1.52% compared with 0.78% with maximal APHR. Simi-
larly, patients with normal submaximal dobutamine SE had
an event rate of 3.11% compared with 1.14% for those who
had maximal APHR (Fig. 2).
Figure 1 Hard Events With Normal SE Comparing Submaximal
Head-to-head comparison of hard events between submaximal and maximal normal st
APHR  age-predicted heart rate; CI  confidence interval; df  degrees of freCARDIAC EVENTS (HARD EVENTS AND REVASCULARIZATION).
Seven studies with 5,798 patients, mean age of 60 years, and
mean follow-up of 34.1 months were included in the
analysis. The risk of total cardiac events with normal SE
(both exercise and dobutamine) was 127% higher in patients
who achieved submaximal compared with those with max-
imal APHR (p  0.0001; 95% CI: 1.54 to 3.34). In 4
studies and 2,464 patients, the risk of total cardiac events
was 141% higher in patients with normal exercise SE with
submaximal compared with those with maximal APHR
(p  0.004; 95% CI: 1.32 to 4.40). Similarly in 3 studies
with 3,334 patients, the risk of total cardiac events was
150% higher in patients with normal dobutamine SE with
submaximal APHR compared with those with maximal
APHR (p  0.01; 95% CI: 1.21 to 5.16) (Fig. 3).
The annualized incidence of total cardiac events in
patients with normal SE with submaximal APHR was
1.87% (102 of 1,310 patients) compared with 1.01% in
patients with maximal APHR (223 of 4,488 patients).
Patients with normal exercise stress test with submaximal
APHR had an annual event rate of 1.71% compared with
0.70% with maximal APHR. Similarly patients with normal
dobutamine SE with submaximal APHR had an event rate
of 3.51% compared with 1.57% for those who underwent
maximal APHR (Fig. 2).
ALL-CAUSE MORTALITY. Two studies with 3,191 patients,
mean age of 58 years, and mean follow-up of 21.4 months
were included in the analysis. There was a trend toward
increased all-cause mortality in patients with normal SE
Maximal APHR
chocardiography (SE).
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October 9, 2012:1393–401 Cardiac Outcomes and Submaximal Stress Echocardiographywith submaximal APHR compared with maximal APHR,
which did not reach statistical significance (p  0.15;
relative risk: 1.36; 95% CI: 0.89 to 2.09).
Prognostic value of submaximal normal versus abnormal SE.
Four studies with 1,486 patients, mean age of 61 years, and
mean follow-up of 26 months were included in the analysis.
The risk of cardiac events was 278% times higher in patients
with submaximal abnormal SE compared with those with
submaximal normal SE (p  0.0001; 95% CI: 2.81 to 5.08)
Fig. 4). The annualized incidence of total cardiac events in
atients with abnormal SE with submaximal APHR was
.37% (75 of 345 patients) compared with 1.78% in patients
ith normal SE with submaximal APHR (67 of 1,141
atients).
ubgroup analysis. Subgroup analysis was performed for
oth hard events and total cardiac events between submaxi-
Figure 2 Annualized Event Rates With Submaximal and Maxim
Annualized rates for both hard events (blue bars) and total cardiac events (%; pur
Figure 3 Total Cardiac Events With Normal SE Comparing Subm
Head-to-head comparison of total cardiac events between submaximal and maximmal and maximal stress testing in various groups like the
presence or absence of resting WMAs, duration of follow-
up, percent of patients on beta-blockers, and age. None of
the groups were significantly different than one another.
Even after exclusion of patients with resting WMAs, there
was a significant increase in the risk of total cardiac events
(p  0.0001) and a trend toward increase in the risk of hard
vents (p  0.07) in patients with normal SE with sub-
aximal APHR compared with patients with maximal
PHR (Table 2).
ublication bias. The shapes of the funnel plots did not
eveal any evidence of obvious asymmetry visually (data
ot shown). There was no evidence of heterogeneity
mong the studies, and tests for publication bias were
egative for each of the analyses by using the Egger
egression test.
rmal SE
rs) with submaximal and maximal normal stress echocardiography (SE).
al With Maximal APHR
al SE. Abbreviations as in Figure 1.al No
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This is the first comprehensive review of the literature
comparing cardiac outcomes with submaximal APHR stress
test versus maximal APHR stress test in patients with
normal SE response. Our meta-analysis showed that pa-
tients with normal SE with submaximal APHR have a
higher risk of both hard events and total cardiac events than
those who achieved maximal APHR. The risk is even
higher in patients with abnormal submaximal stress test
compared with normal submaximal stress test. In addition,
there is a trend toward increased all-cause mortality in
patients undergoing normal SE with submaximal APHR
when compared with maximal APHR.
The reported incidence of submaximal stress testing
varies in different studies and in different patient popula-
tions. Patients with hypertension, diabetes, prior MI, older
age, typical angina symptoms; men; African Americans; and
those on calcium channel blockers and beta-blockers are
more likely to undergo submaximal stress testing (8,12,16).
Given the increased risk of cardiovascular events for sub-
maximal stress test, it is important to take all of these factors
into consideration when ordering a stress test. Patients
should be advised to hold their atrioventricular nodal
blockers on the day of the stress test. If the patient fails to
achieve APHR with exercise, the protocol should be
switched to dobutamine SE in the absence of any contra-
indication. Maximal doses of dobutamine (50 g/kg/min)
nd atropine (2 mg) should be administered in the absence
f severe side effects, arrhythmias, or hypertension to
chieve APHR.
Our study did not show any significant difference in
ll-cause mortality in patients with normal SE undergoing
ubmaximal APHR compared with patients with maximal
Figure 4 Total Cardiac Events Comparing Submaximal Abnorm
Head-to-head comparison of total cardiac events between submaximal abnormal (aPHR; however, there was a trend toward increased mor- cality in patients with submaximal APHR. These data
hould be interpreted with caution because only 2 studies
rovided the data on mortality with normal SE. Several
ther large studies with more than 4,000 patients have
eported significantly increased mortality in patients under-
oing submaximal stress testing compared with those with
aximal APHR (34,39,40). However, these studies did not
eport outcomes separately for patients with normal versus
bnormal SE results and hence were excluded from our
tudy.
Our study did not show any significant difference in
ardiac outcomes with respect to beta-blocker use. In a
tudy of 661 patients, no relation was found between the use
f beta-blockers and cardiac events (41). In fact, beta-
locker therapy may have a protective effect in patients
ndergoing submaximal stress test because they were found
o have a lower number of cardiac events compared with
hose patients who underwent submaximal test without
eta-blocker use (7). In another large study of 5,375 patients
ith normal exercise SE, beta-blocker therapy was found to
e protective, with patients having significantly less mortal-
ty (40). Two plausible scenarios can explain the lower
ardiac outcomes in patients on beta-blockers. The first
xplanation is the reduced heart rate exclusively due to
eta-blocker therapy and not related to either decondition-
ng or chronotropic incompetence; thus, these patients are
isease free. The second explanation is the cardioprotective
ffect of beta-blockers in patients with underlying CAD;
hus, in these patients, beta-blockers provide the anticipated
eneficial protective effect.
Our study has important clinical implications because
atients with normal SE with submaximal APHR have
orse cardiac outcomes. Several factors should be taken into
th Submaximal Normal SE
nd submaximal normal (nl) SE. Abbreviations as in Figure 1.al Wi
bnl) aonsideration while making further clinical decisions. It is
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October 9, 2012:1393–401 Cardiac Outcomes and Submaximal Stress Echocardiographybeyond the scope of this paper to identify patients who
might be at risk of worse cardiac outcomes. However, prior
studies have suggested that patients with high-risk features
as listed in Table 3 (6–8,13,26,28,32,40,42–49) have worse
ardiac outcomes and therefore should get further cardiac
Subgroup AnalysisTable 2 Subgroup Analysis
Subgroups
No. of
Studies
No. of
Events
No. of
Patients
Hard events Submaximal
Resting WMA
Yes 1 21 130
No 5 22 315
Unclear* 3 41 775
Duration, yrs
3 5 19 531
3 3 59 539
Patients on beta-blockers, %
20 3 25 519
20 3 32 360
Mean age, yrs
60 3 6 102
60 5 78 1,118
Total cardiac events Submaximal
Resting WMA
Yes 0
No 4 30 376
Unclear* 3 72 934
Duration, yrs
3 4 33 789
3 3 69 521
Patients on beta-blockers, %
20 3 25 330
20 4 77 980
Mean age, yrs
60 4 20 332
60 3 82 978
*Unclear included studies that enrolled patients with and without resting WMA but did not provid
CI  confidence interval; RR  relative risk; WMA  wall motion abnormality.
Recommendations forNormal SE Wi h Submaximal APHRTable 3 Recommendations forNormal SE With Submaximal APHR
Further workup indicated
1. High-risk population (prior MI, PCI, CABG, DM, PAD, HF with EF 40%)
2. Limited exercise capacity (7 METs for men, 5 METs for women)
3. Evidence of arrhythmias, hypotension, severe hypertension during the stress
4. Significant electrocardiographic abnormalities during or after stress
5. Patients with moderate or severe renal dysfunction* (CrCl 60)
6. Intermediate- or high-risk Duke treadmill score (4)
7. Resting wall-motion abnormalities
8. Chest pain during stress testing
9. Echocardiographic evidence of left ventricular hypertrophy
10. Advanced age, male sex
No further workup indicated
1. Asymptomatic patient/atypical symptoms with minimal or no risk factors
2. Good exercise capacity (7 METs for men, 5 METs for women)
*Evidence available in patients undergoing dobutamine SE.
CABG  coronary artery bypass grafting; CrCl  creatinine clearance; DM  diabetes mellitus;o
EF  ejection fraction; HF  heart failure; MET  metabolic equivalent; PAD  peripheral arterial
disease; PCI  percutaneous coronary intervention; other abbreviations as in Table 1.orkup in our opinion. In contrast, patients with minimal
isk factors with good exercise capacity (6,14,29) may be
onitored safely without further workup.
tudy limitations. The results of this meta-analysis are
ubject to limitations and bias inherent to any meta-analysis
ased on pooling of data from different studies with differ-
nt designs, durations, and patient groups. Also, the prog-
ostic value of a test is prone to referral bias. All of the
ncluded studies had patients with known or suspected
AD with a wide spectrum of pre-test probabilities of
isease; thus, outcomes may differ. There is also potential
or bias from unmeasured confounding in observational
tudies. The baseline characteristics of patients with sub-
aximal stress test were significantly different than those
ith maximal stress test. These factors might be responsible
or a higher event rate in patients with submaximal test;
hus, it is important to recognize these factors before
nterpreting a normal stress test with submaximal APHR.
onclusions
ubmaximal APHR with normal SE portends a higher risk
of
nts
No. of
Patients RR
Ratio of RR
(95% CI)
Interaction
p Value
imal
0.75
9 107 1.9 (0.9–4.0) 1.1 (0.5–2.3)
6 691 1.8 (1.0–3.3)
7 2,559 1.6 (1.1–2.4)
0.37
4 2,476 2.1 (1.2–3.5) 1.3 (0.7–2.6)
2 729 1.6 (1.1–2.3)
0.54
5 2,207 2.2 (1.3–3.9) 1.3 (0.6–2.7)
7 579 1.7 (1.0–2.9)
0.64
4 454 2.2 (0.8–6.0) 1.3 (0.5–3.7)
8 2,903 1.7 (1.2–2.3)
imal
0.06
5 1,439 3.2 (1.9–5.6) 1.78 (0.9–3.3)
8 3,049 1.8 (1.4–2.4)
0.06
5 1,703 3.5 (1.8–6.8) 1.97 (0.9–3.9)
8 2,785 1.8 (1.4–2.3)
0.40
5 1,287 2.1 (1.2–3.7) 0.65 (0.2–1.8)
8 3,201 3.3 (1.4–7.5)
0.24
5 1,535 3.3 (1.3–7.9) 1.75 (0.7–4.5)
8 2,953 1.9 (1.4–2.4)
s separately for both groups.No.
Eve
Max
2
5
4
4
3
2
1
7
Max
2
19
2
19
3
18
3
18f both hard events and total cardiac events compared with
1400 Makani et al. JACC Vol. 60, No. 15, 2012
Cardiac Outcomes and Submaximal Stress Echocardiography October 9, 2012:1393–401maximal APHR. The risk is even higher and persists in
patients with abnormal stress echocardiogram. Thus, the
results of submaximal APHR in the setting of a normal SE
should be taken into consideration for more accurate risk
stratification and prognosis.
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